EML4 and non-small cell lung carcinoma: We found that clinical factors such as prior anticancer therapy and ECOG performance status were independent factors for crizotinib PFS in advanced NSCLC bearing EML4–ALK fusion, while ALK fusion variants and BIM polymorphism were not.